查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866598

呼吸系统药物：全球市场占有率和排名、总销售额和需求预测（2025-2031年）

Respiratory Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 122 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年全球呼吸系统药物市场规模估计为512.31亿美元，预计到2031年将达到746.45亿美元，2025年至2031年的复合年增长率为5.5%。

本报告对近期呼吸系统药物的关税调整和国际战略应对措施进行了全面评估，包括跨境产业布局、资本配置模式、区域经济相互依存以及供应链重组。

呼吸系统药物是一个总称，涵盖用于缓解、治疗和预防呼吸系统疾病的各种药物，例如气喘、慢性支气管炎、慢性阻塞性肺病（COPD）和肺炎。 2024年，全球呼吸系统药物产量约38.51亿片，全球平均市场价格约为每片13.3美元。

全球呼吸系统疾病患者数量持续成长，其中慢性阻塞性肺病（COPD）、气喘和其他慢性呼吸系统疾病构成了主要患者群体，并推动了对药品的强劲需求。世界各国政府和监管机构已出台政策，支持创新药物研发、吸入製剂的生物等效性评估以及慢性病管理，从而加速了新型和改良製剂的上市。根据主要製药公司的年度报告，吸入疗法和生物製药的年增长率显着，研发投入和专利组合巩固了市场的长期扩张。证券研究表明，未来五年内，与数位健康平台的整合以及用于个人化治疗的远端监测有望显着提高市场渗透率。日益严重的空气污染、人口老化以及对慢性病管理的需求正在推动市场成长，而创新药物和高附加价值製剂则是关键的差异化因素。

呼吸系统药物产业面临高昂的研发成本、漫长的研发週期和严格的监管要求。年度报告指出，原物料价格波动以及对进口中间体和原料药的依赖增加了生产风险。健保报销目录的调整和基于采购量的采购政策可能会挤压学名药的利润空间，而高端创新药则依赖患者的依从性和临床证据。各国监管政策的差异也使跨境市场进入变得更加复杂。在竞争激烈的市场环境中，创新药必须展现临床优势、病患体验优势和差异化服务，才能确保重复购买和市场占有率。

终端用户的需求正朝着精准化、个人化和全週期管理的方向发展。家庭慢性病管理和远距医疗平台的兴起推动了吸入疗法、智慧雾化器和个人化药物剂量方案的普及。医疗机构倾向于选择与电子健康记录、远端监测和分析平台整合的产品，以便追踪疗效和监测用药依从性。中介分析表明，联合治疗、可调节剂量和数位化管理功能是关键的差异化因素，而数据分析和远端追踪则为慢性病管理和患者教育带来长期价值。

本报告旨在按地区/国家、类型和应用对全球呼吸系统药物市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

呼吸系统药物市场规模、估计值和预测以销售（百万）和收入（百万美元）为单位呈现，基准年为2024年，并包含2020年至2031年的历史数据和预测数据。定量和定性分析相结合，有助于读者制定业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并就呼吸系统药物做出明智的商业决策。

市场区隔

公司

  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Vertex
  • Roche
  • Novartis
  • Teva
  • Chiesi
  • Mylan
  • Sumitomo Dainippon
  • Merck
  • Beximco

按类型分類的细分市场

  • 吸入剂和鼻喷雾
  • 口服
  • 其他的

应用领域

  • 医院
  • 药局

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Respiratory Drug was estimated to be worth US$ 51231 million in 2024 and is forecast to a readjusted size of US$ 74645 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Respiratory Drug cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. In 2024, global Respiratory drug production reached approximately 3851 m units, with an average global market price of around US$ 13.3 perunit.

The global population of respiratory disease patients continues to grow, with COPD, asthma, and chronic respiratory conditions representing a substantial patient base, driving strong demand for medications. Governments and regulators are introducing policies to support innovative drug development, bioequivalence evaluation of inhaled formulations, and chronic disease management, accelerating the launch of new drugs and improved formulations. Annual reports of leading pharmaceutical companies indicate significant year-on-year growth in inhaled therapies and biologics, with R&D investment and patent portfolios securing long-term market expansion. Brokerage research suggests that integration with digital health platforms and remote monitoring for personalized therapy could significantly increase market penetration over the next five years. Rising air pollution, aging populations, and chronic disease management needs sustain market growth, with innovative drugs and high-value formulations as key differentiators.

The respiratory drug sector faces high R&D costs, long development cycles, and strict regulatory requirements. Annual reports highlight that raw material price volatility and reliance on imported intermediates or APIs increase production risks. Adjustments to reimbursement lists and volume-based procurement policies may compress margins for generic drugs, while high-end innovative products depend on patient adherence and clinical evidence. Regulatory differences across countries complicate cross-border market entry. Intense competition requires new products to demonstrate clinical advantage, patient experience benefits, and differentiated services to secure repeat purchases and market share.

End-user demand is shifting toward precision, personalization, and full-cycle management. The growth of home chronic disease management and remote healthcare platforms is driving increased adoption of inhaled therapies, smart nebulizers, and personalized dosage medications. Healthcare institutions favor products integrated with electronic medical records, remote monitoring, and analytics platforms for efficacy tracking and adherence monitoring. Brokerage analyses indicate that combination therapies, adjustable dosages, and digital management capabilities will become key differentiators, while data analytics and remote follow-up enable long-term value in chronic disease management and patient education.

This report aims to provide a comprehensive presentation of the global market for Respiratory Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Respiratory Drug by region & country, by Type, and by Application.

The Respiratory Drug market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Drug.

Market Segmentation

By Company

  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Vertex
  • Roche
  • Novartis
  • Teva
  • Chiesi
  • Mylan
  • Sumitomo Dainippon
  • Merck
  • Beximco

Segment by Type

  • Inhalable & Nasal Spray
  • Oral
  • Others

Segment by Application

  • Hospital
  • Drugs Store

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Respiratory Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Respiratory Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Respiratory Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Respiratory Drug Product Introduction
  • 1.2 Global Respiratory Drug Market Size Forecast
    • 1.2.1 Global Respiratory Drug Sales Value (2020-2031)
    • 1.2.2 Global Respiratory Drug Sales Volume (2020-2031)
    • 1.2.3 Global Respiratory Drug Sales Price (2020-2031)
  • 1.3 Respiratory Drug Market Trends & Drivers
    • 1.3.1 Respiratory Drug Industry Trends
    • 1.3.2 Respiratory Drug Market Drivers & Opportunity
    • 1.3.3 Respiratory Drug Market Challenges
    • 1.3.4 Respiratory Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Respiratory Drug Players Revenue Ranking (2024)
  • 2.2 Global Respiratory Drug Revenue by Company (2020-2025)
  • 2.3 Global Respiratory Drug Players Sales Volume Ranking (2024)
  • 2.4 Global Respiratory Drug Sales Volume by Company Players (2020-2025)
  • 2.5 Global Respiratory Drug Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Respiratory Drug Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Respiratory Drug Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Respiratory Drug
  • 2.9 Respiratory Drug Market Competitive Analysis
    • 2.9.1 Respiratory Drug Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Respiratory Drug Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Drug as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Inhalable & Nasal Spray
    • 3.1.2 Oral
    • 3.1.3 Others
  • 3.2 Global Respiratory Drug Sales Value by Type
    • 3.2.1 Global Respiratory Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Respiratory Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Respiratory Drug Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Respiratory Drug Sales Volume by Type
    • 3.3.1 Global Respiratory Drug Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Respiratory Drug Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Respiratory Drug Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Respiratory Drug Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Drugs Store
  • 4.2 Global Respiratory Drug Sales Value by Application
    • 4.2.1 Global Respiratory Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Respiratory Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Respiratory Drug Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Respiratory Drug Sales Volume by Application
    • 4.3.1 Global Respiratory Drug Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Respiratory Drug Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Respiratory Drug Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Respiratory Drug Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Respiratory Drug Sales Value by Region
    • 5.1.1 Global Respiratory Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Respiratory Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Respiratory Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Respiratory Drug Sales Value by Region (%), (2020-2031)
  • 5.2 Global Respiratory Drug Sales Volume by Region
    • 5.2.1 Global Respiratory Drug Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Respiratory Drug Sales Volume by Region (2020-2025)
    • 5.2.3 Global Respiratory Drug Sales Volume by Region (2026-2031)
    • 5.2.4 Global Respiratory Drug Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Respiratory Drug Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Respiratory Drug Sales Value, 2020-2031
    • 5.4.2 North America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Respiratory Drug Sales Value, 2020-2031
    • 5.5.2 Europe Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Respiratory Drug Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Respiratory Drug Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Respiratory Drug Sales Value, 2020-2031
    • 5.7.2 South America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Respiratory Drug Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Respiratory Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Respiratory Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Respiratory Drug Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Respiratory Drug Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Respiratory Drug Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Respiratory Drug Sales Value, 2020-2031
    • 6.3.2 United States Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Respiratory Drug Sales Value, 2020-2031
    • 6.4.2 Europe Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Respiratory Drug Sales Value, 2020-2031
    • 6.5.2 China Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Respiratory Drug Sales Value, 2020-2031
    • 6.6.2 Japan Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Respiratory Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Respiratory Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Respiratory Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Respiratory Drug Sales Value, 2020-2031
    • 6.9.2 India Respiratory Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Respiratory Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 GSK
    • 7.1.1 GSK Company Information
    • 7.1.2 GSK Introduction and Business Overview
    • 7.1.3 GSK Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 GSK Respiratory Drug Product Offerings
    • 7.1.5 GSK Recent Development
  • 7.2 AstraZeneca
    • 7.2.1 AstraZeneca Company Information
    • 7.2.2 AstraZeneca Introduction and Business Overview
    • 7.2.3 AstraZeneca Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 AstraZeneca Respiratory Drug Product Offerings
    • 7.2.5 AstraZeneca Recent Development
  • 7.3 Boehringer Ingelheim
    • 7.3.1 Boehringer Ingelheim Company Information
    • 7.3.2 Boehringer Ingelheim Introduction and Business Overview
    • 7.3.3 Boehringer Ingelheim Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Boehringer Ingelheim Respiratory Drug Product Offerings
    • 7.3.5 Boehringer Ingelheim Recent Development
  • 7.4 Vertex
    • 7.4.1 Vertex Company Information
    • 7.4.2 Vertex Introduction and Business Overview
    • 7.4.3 Vertex Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Vertex Respiratory Drug Product Offerings
    • 7.4.5 Vertex Recent Development
  • 7.5 Roche
    • 7.5.1 Roche Company Information
    • 7.5.2 Roche Introduction and Business Overview
    • 7.5.3 Roche Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Roche Respiratory Drug Product Offerings
    • 7.5.5 Roche Recent Development
  • 7.6 Novartis
    • 7.6.1 Novartis Company Information
    • 7.6.2 Novartis Introduction and Business Overview
    • 7.6.3 Novartis Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Novartis Respiratory Drug Product Offerings
    • 7.6.5 Novartis Recent Development
  • 7.7 Teva
    • 7.7.1 Teva Company Information
    • 7.7.2 Teva Introduction and Business Overview
    • 7.7.3 Teva Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Teva Respiratory Drug Product Offerings
    • 7.7.5 Teva Recent Development
  • 7.8 Chiesi
    • 7.8.1 Chiesi Company Information
    • 7.8.2 Chiesi Introduction and Business Overview
    • 7.8.3 Chiesi Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Chiesi Respiratory Drug Product Offerings
    • 7.8.5 Chiesi Recent Development
  • 7.9 Mylan
    • 7.9.1 Mylan Company Information
    • 7.9.2 Mylan Introduction and Business Overview
    • 7.9.3 Mylan Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Mylan Respiratory Drug Product Offerings
    • 7.9.5 Mylan Recent Development
  • 7.10 Sumitomo Dainippon
    • 7.10.1 Sumitomo Dainippon Company Information
    • 7.10.2 Sumitomo Dainippon Introduction and Business Overview
    • 7.10.3 Sumitomo Dainippon Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Sumitomo Dainippon Respiratory Drug Product Offerings
    • 7.10.5 Sumitomo Dainippon Recent Development
  • 7.11 Merck
    • 7.11.1 Merck Company Information
    • 7.11.2 Merck Introduction and Business Overview
    • 7.11.3 Merck Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Merck Respiratory Drug Product Offerings
    • 7.11.5 Merck Recent Development
  • 7.12 Beximco
    • 7.12.1 Beximco Company Information
    • 7.12.2 Beximco Introduction and Business Overview
    • 7.12.3 Beximco Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Beximco Respiratory Drug Product Offerings
    • 7.12.5 Beximco Recent Development

8 Industry Chain Analysis

  • 8.1 Respiratory Drug Industrial Chain
  • 8.2 Respiratory Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Respiratory Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Respiratory Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Respiratory Drug Market Trends
  • Table 2. Respiratory Drug Market Drivers & Opportunity
  • Table 3. Respiratory Drug Market Challenges
  • Table 4. Respiratory Drug Market Restraints
  • Table 5. Global Respiratory Drug Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Respiratory Drug Revenue Market Share by Company (2020-2025)
  • Table 7. Global Respiratory Drug Sales Volume by Company (2020-2025) & (M Units)
  • Table 8. Global Respiratory Drug Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Respiratory Drug Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers Respiratory Drug Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Respiratory Drug Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Respiratory Drug
  • Table 13. Global Respiratory Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Drug as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Respiratory Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Respiratory Drug Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Respiratory Drug Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Respiratory Drug Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Respiratory Drug Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Respiratory Drug Sales Volume by Type: 2020 VS 2024 VS 2031 (M Units)
  • Table 22. Global Respiratory Drug Sales Volume by Type (2020-2025) & (M Units)
  • Table 23. Global Respiratory Drug Sales Volume by Type (2026-2031) & (M Units)
  • Table 24. Global Respiratory Drug Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Respiratory Drug Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Respiratory Drug Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global Respiratory Drug Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global Respiratory Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Respiratory Drug Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Respiratory Drug Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Respiratory Drug Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Respiratory Drug Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Respiratory Drug Sales Volume by Application: 2020 VS 2024 VS 2031 (M Units)
  • Table 34. Global Respiratory Drug Sales Volume by Application (2020-2025) & (M Units)
  • Table 35. Global Respiratory Drug Sales Volume by Application (2026-2031) & (M Units)
  • Table 36. Global Respiratory Drug Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Respiratory Drug Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Respiratory Drug Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global Respiratory Drug Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global Respiratory Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Respiratory Drug Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Respiratory Drug Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Respiratory Drug Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Respiratory Drug Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Respiratory Drug Sales Volume by Region (M Units): 2020 VS 2024 VS 2031
  • Table 46. Global Respiratory Drug Sales Volume by Region (2020-2025) & (M Units)
  • Table 47. Global Respiratory Drug Sales Volume by Region (2026-2031) & (M Units)
  • Table 48. Global Respiratory Drug Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Respiratory Drug Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Respiratory Drug Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global Respiratory Drug Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions Respiratory Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Respiratory Drug Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Respiratory Drug Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Respiratory Drug Sales Volume, (2020-2025) & (M Units)
  • Table 56. Key Countries/Regions Respiratory Drug Sales Volume, (2026-2031) & (M Units)
  • Table 57. GSK Company Information
  • Table 58. GSK Introduction and Business Overview
  • Table 59. GSK Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. GSK Respiratory Drug Product Offerings
  • Table 61. GSK Recent Development
  • Table 62. AstraZeneca Company Information
  • Table 63. AstraZeneca Introduction and Business Overview
  • Table 64. AstraZeneca Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. AstraZeneca Respiratory Drug Product Offerings
  • Table 66. AstraZeneca Recent Development
  • Table 67. Boehringer Ingelheim Company Information
  • Table 68. Boehringer Ingelheim Introduction and Business Overview
  • Table 69. Boehringer Ingelheim Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Boehringer Ingelheim Respiratory Drug Product Offerings
  • Table 71. Boehringer Ingelheim Recent Development
  • Table 72. Vertex Company Information
  • Table 73. Vertex Introduction and Business Overview
  • Table 74. Vertex Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Vertex Respiratory Drug Product Offerings
  • Table 76. Vertex Recent Development
  • Table 77. Roche Company Information
  • Table 78. Roche Introduction and Business Overview
  • Table 79. Roche Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. Roche Respiratory Drug Product Offerings
  • Table 81. Roche Recent Development
  • Table 82. Novartis Company Information
  • Table 83. Novartis Introduction and Business Overview
  • Table 84. Novartis Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. Novartis Respiratory Drug Product Offerings
  • Table 86. Novartis Recent Development
  • Table 87. Teva Company Information
  • Table 88. Teva Introduction and Business Overview
  • Table 89. Teva Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. Teva Respiratory Drug Product Offerings
  • Table 91. Teva Recent Development
  • Table 92. Chiesi Company Information
  • Table 93. Chiesi Introduction and Business Overview
  • Table 94. Chiesi Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 95. Chiesi Respiratory Drug Product Offerings
  • Table 96. Chiesi Recent Development
  • Table 97. Mylan Company Information
  • Table 98. Mylan Introduction and Business Overview
  • Table 99. Mylan Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 100. Mylan Respiratory Drug Product Offerings
  • Table 101. Mylan Recent Development
  • Table 102. Sumitomo Dainippon Company Information
  • Table 103. Sumitomo Dainippon Introduction and Business Overview
  • Table 104. Sumitomo Dainippon Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 105. Sumitomo Dainippon Respiratory Drug Product Offerings
  • Table 106. Sumitomo Dainippon Recent Development
  • Table 107. Merck Company Information
  • Table 108. Merck Introduction and Business Overview
  • Table 109. Merck Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 110. Merck Respiratory Drug Product Offerings
  • Table 111. Merck Recent Development
  • Table 112. Beximco Company Information
  • Table 113. Beximco Introduction and Business Overview
  • Table 114. Beximco Respiratory Drug Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 115. Beximco Respiratory Drug Product Offerings
  • Table 116. Beximco Recent Development
  • Table 117. Key Raw Materials Lists
  • Table 118. Raw Materials Key Suppliers Lists
  • Table 119. Respiratory Drug Downstream Customers
  • Table 120. Respiratory Drug Distributors List
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Respiratory Drug Product Picture
  • Figure 2. Global Respiratory Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Respiratory Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Respiratory Drug Sales Volume (2020-2031) & (M Units)
  • Figure 5. Global Respiratory Drug Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. Respiratory Drug Report Years Considered
  • Figure 7. Global Respiratory Drug Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Respiratory Drug Players Sales Volume Ranking (2024) & (M Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Respiratory Drug Revenue in 2024
  • Figure 10. Respiratory Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Inhalable & Nasal Spray Picture
  • Figure 12. Oral Picture
  • Figure 13. Others Picture
  • Figure 14. Global Respiratory Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Respiratory Drug Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Respiratory Drug Sales Volume by Type (2020 VS 2024 VS 2031) & (M Units)
  • Figure 17. Global Respiratory Drug Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Respiratory Drug Price by Type (2020-2031) & (US$/Unit)
  • Figure 19. Product Picture of Hospital
  • Figure 20. Product Picture of Drugs Store
  • Figure 21. Global Respiratory Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Respiratory Drug Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Respiratory Drug Sales Volume by Application (2020 VS 2024 VS 2031) & (M Units)
  • Figure 24. Global Respiratory Drug Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Respiratory Drug Price by Application (2020-2031) & (US$/Unit)
  • Figure 26. North America Respiratory Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Respiratory Drug Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Respiratory Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Respiratory Drug Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Respiratory Drug Sales Volume (%), (2020-2031)
  • Figure 38. United States Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Respiratory Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Respiratory Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Respiratory Drug Industrial Chain
  • Figure 60. Respiratory Drug Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed